We’re living in interesting times and I mean that in the Chinese curse kind of way. We can’t seem to stop to catch our breath when it comes to…
Search Results for: MYND.C
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals…
Looking at the charts of the Psychedelics sector, they can best be described as a mixed bag. Just like Cannabis, shroom stocks are taking a hit. This could just…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
MYND Life Sciences (MYND.C) announced they have signed a Letter of Intent (LOI) with Eyam Vaccines and Immunotherapies which outlines an Exclusive Licensing Agreement with respect to Eyam’s proprietary…
A different approach to MDD I’m big on companies having a unique approach to whatever they are doing. Many psychedelics companies are targetting depression but from a psychedelic-assisted therapy…
Back in October, Zuckerberg, seeing plunging user numbers and fading growth, desperately renamed Facebook, once the world’s foremost purveyor of misinformation and unethical aggregator of personal data, to Meta,…
Environmental, Social and Governance (ESG) focused investment is a relatively new accepted method for socially conscious investors to allocate their investment capital in public/private companies that align with their…
Health Canada stepped up to the plate back in December with a Notice of Intent to amend the Food and Drug Regulations and the Narcotic Control Regulations to restore…